Novo Nordisk AS has released the latest data set from its ten PIONEER studies evaluating oral semaglutide, saying that the Phase IIIa PIONEER 5 trial showed its once-daily oral GLP-1 analog hit the trial goals of reducing blood sugar levels and weight in adults with type-2 diabetes.
Results of the 26-week PIONEER 5 trial, which involved 324 people with type 2 diabetes and moderate renal impairment, showed that those treated with 14 mg oral semaglutide saw a 1.1% reduction in HbA1c compared with a 0.1% decline for placebo
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?